by Alexandra Atkins, PhD | Feb 13, 2019 | Blog
Clinical drug trials in preclinical AD populations require novel approaches to participant identification, screening, and enrollment. Execution of these trials requires rapid development of cognitive screening instruments that are straightforward, sensitive to...
by Alexandra Atkins, PhD | Jan 10, 2019 | Blog
Clinical trials in mild to moderate Alzheimer’s Disease (AD) rely on informant reports to characterize study participants’ performance on basic and instrumental activities of daily living. As clinical trials move earlier in the AD continuum, however, these...
